Novo Nordisk has appointed Mr. Venkat Kalyan as General Manager for Novo Nordisk Gulf. The appointment reinforces the company’s confidence in the Gulf’s evolving healthcare ecosystem and the UAE’s growing role as a strategic centre for medical research, innovation, and partnership-led growth.
In this role, Mr. Kalyan will oversee Novo Nordisk’s operations across the UAE, Qatar, Kuwait, Bahrain, Oman, and Yemen. He will focus on strengthening healthcare partnerships, advancing innovation, and improving outcomes for patients living with chronic diseases.
Mr. Kalyan commented: “The Gulf markets hold real potential and are exceptionally well positioned to lead the next phase of healthcare transformation. I look forward to building on Novo Nordisk’s strong foundation in the region and working closely with all our healthcare stakeholders to improve outcomes for patients.”
Mr. Kalyan brings nearly 30 years of experience in the pharmaceutical and healthcare sector, including 18 years at Novo Nordisk, most recently as General Manager of the Gulf Emerging Markets Cluster. His prior leadership experience spans across diverse markets such as India, Switzerland, Denmark, Middle Africa, South Africa and Gulf countries.
With its rapidly evolving healthcare landscape, the Gulf markets have become an integral part of Novo Nordisk’s global growth strategy, as the company renews its commitment to expanding its impact across the region and advancing accessible and sustainable patient care systems for these communities.
